Cellectis SEC Filings

Cellectis filed a Form 6-K to report the results of its shareholders general meeting held on June 25, 2026 in Paris. At this meeting, about 55.84% of voting rights were exercised. Resolutions 1 through 29 were adopted and resolution 30 was rejected, in line with the board of directors’ recommendations. Detailed voting results are available on the company’s website. Cellectis is a clinical-stage biotechnology company developing gene-edited, off-the-shelf CAR T-cell therapies and other gene therapies, with shares listed on Nasdaq and Euronext Growth.

Cellectis S.A. reported the results of its Combined General Meeting of Shareholders held on June 25, 2026. Shareholders approved the 2025 annual and consolidated financial statements, allocation of results, and review of regulated agreements, with around 99.9% of votes in favor on the core financial items.

The meeting renewed four directors, including Jean‑Pierre Garnier and Cécile Chartier, and authorized the Board to repurchase shares and cancel repurchased shares, each with more than 99% support. A broad set of capital increase delegations was approved, many with cancellation of preferential subscription rights for targeted investor categories, including an equity financing program on the U.S. market through an “at‑the‑market” facility.

Shareholders also approved authorizations for stock options and free share grants, as well as related caps, and amended bylaws to reflect new legal provisions. One item, a capital increase reserved for members of a company savings plan, was rejected, receiving about 14.8% votes in favor and 85.2% against. Quorum reached 55.840%, with 46,175,805 shares represented, or 45.858% of the share capital.

Cellectis reported new clinical data for its allogeneic CAR-T candidates lasme-cel and eti-cel at the EHA 2026 congress. In the BALLI-01 Phase 1 trial’s target Phase 2 population for relapsed/refractory B-ALL, lasme-cel achieved a 100% overall response rate (7/7) with 57% (4/7) complete remission or complete remission with incomplete count recovery, and 75% of these responders reached MRD-negative status before all proceeded to stem cell transplant.

Lasme-cel showed a manageable safety profile, with grade ≥3 cytokine release syndrome in 4% of patients, immune effector cell-associated neurotoxicity in 4%, and IEC-HS in 2%, all resolving. In NATHALI-01 for relapsed/refractory B-NHL, eti-cel produced an 88% overall response rate and 63% complete response rate in the optimal dose cohort, while analyses linked higher alemtuzumab exposure and sustained low-level IL-2 secretion to improved expansion and responses. The pivotal Phase 2 BALLI-01 and the Phase 1 NATHALI-01 studies are both open for recruitment, with key data readouts expected in Q4 2026.

Cellectis reported that the U.S. Food and Drug Administration granted Regenerative Medicine Advanced Therapy (RMAT) designation to lasmecabtagene timgedleucel (lasme-cel), its CD22‑targeting allogeneic CAR‑T cell therapy candidate for patients with relapsed or refractory B‑cell acute lymphoblastic leukemia. The company states this designation reflects FDA recognition of lasme‑cel’s potential to address unmet medical need, based on Phase 1 BALLI‑01 data showing promising efficacy and a manageable safety profile. Final Phase 1 BALLI‑01 data will be presented in an oral session at the 2026 European Hematology Association Congress on June 13. A pivotal Phase 2 portion of the BALLI‑01 trial is open for enrollment.

Cellectis S.A. is convening a combined general meeting of shareholders on June 25, 2026 in Paris to approve 2025 accounts, board renewals and extensive capital authorizations. The 2025 annual financial statements show a loss of 61,849,605 euros, while consolidated accounts show a loss of 67,592,758 US dollars. The loss will be allocated to retained earnings, which will then be cleared by transferring 61,849,605 euros from the share premium account, reducing it from 194,582,155.02 euros to 132,732,550.02 euros. Shareholders are asked to renew a share buyback program with a maximum unit price of 10 euros, a total cap of 10,000,000 euros and a limit of 10% of outstanding shares, with possible cancellation of up to 10% of capital every 24 months. Numerous resolutions would delegate to the board the power to issue new shares and securities, often with cancellation of preferential subscription rights, with aggregate nominal caps generally set at 2,514,775 euros (50% of current share capital of 5,029,549.70 euros) and debt issuance ceilings of up to 300,000,000 euros, including targeted issuances to sector investors, financing partners, development banks and via an at-the-market program in the U.S.

Cellectis S.A. has scheduled its annual shareholders general meeting for June 25, 2026 at 2:30 p.m. CET at the Biopark auditorium, 11 rue Watt, 4th floor, 75013 Paris, France. The formal notice and related meeting information are available on the company’s investor website.

Cellectis, a clinical-stage gene-editing company, announced that new clinical data on its allogeneic CAR-T candidates lasme-cel and eti-cel will be presented at the EHA 2026 congress in Stockholm. An oral presentation will cover full Phase 1 BALLI-01 results in relapsed or refractory B-cell acute lymphoblastic leukemia, which support a pivotal Phase 2 program now recruiting in Europe and North America. A poster will present preliminary Phase 1 NATHALI-01 data in relapsed or refractory B-cell non-Hodgkin lymphoma, exploring how alemtuzumab exposure and cytokine dynamics relate to expansion and response of the dual-targeting CD20/CD22 product. Interim BALLI-01 Phase 2 data and Phase 1 NATHALI-01 clinical data are planned to be disclosed in Q4 2026.

Cellectis reported a consolidated net loss attributable to shareholders of $17.8 million, or $0.18 per share, for the first quarter of 2026, similar to the prior year. Revenue and other income fell to $7.5 million from $12.0 million, mainly due to lower activity under the AstraZeneca collaboration, while R&D and SG&A expenses increased as the company invested in its pipeline.

The company ended March 31 2026 with $188 million in cash, cash equivalents, restricted cash and fixed-term deposits and believes this will fund operations into Q4 2027. Key programs include the pivotal Phase 2 BALLI‑01 trial of lasme‑cel in relapsed or refractory B‑ALL, with a first interim analysis expected in Q4 2026 and a planned BLA submission in 2028, and the Phase 1 NATHALI‑01 trial of eti‑cel in relapsed or refractory NHL, with a full Phase 1 dataset also expected in Q4 2026.

Cellectis highlighted interim pivotal ALPHA3 data from partner Allogene’s cema‑cel program, showing 58.3% MRD negativity in the cema‑cel arm versus 16.7% in the observation arm and a favorable safety profile. The company is also advancing a TALE‑based epigenetic editing platform and continues its AstraZeneca collaboration. Subsequently, Life Technologies Corporation, a Thermo Fisher subsidiary, purported to terminate certain license agreements and initiated arbitration over alleged underpaid royalties, which Cellectis contests.

Cellectis S.A. reported unaudited results for the three-month period ended March 31, 2026. Total revenues and other income were $7.5 million, down from $12.0 million a year earlier, mainly reflecting lower collaboration revenue recognized under its AstraZeneca joint research and collaboration agreement.

Research and development expenses rose to $27.2 million from $21.9 million, driven by higher personnel costs and clinical spending on the BALLI-01 and NATHALI-01 studies. The company posted an operating loss of $25.2 million and a net loss of $17.8 million, similar to the prior-year net loss, with earnings per share at $(0.18). A $6.5 million fair value gain on EIB warrants contributed to a net financial gain of $7.4 million. Cash and cash equivalents stood at $34.8 million, with an additional $150.6 million in fixed-term deposits classified as current financial assets, and management states these resources are sufficient to fund operations for at least twelve months after approval of the statements.